Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cataract - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H2 2016, provides an overview of the Cataract (Ophthalmology) pipeline landscape. Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Cataract. Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cataract Overview 6 Therapeutics Development 7 Pipeline Products for Cataract - Overview 7 Pipeline Products for Cataract - Comparative Analysis 8 Cataract - Therapeutics under Development by Companies 9 Cataract - Therapeutics under Investigation by Universities/Institutes 10 Cataract - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Cataract - Products under Development by Companies 13 Cataract - Products under Investigation by Universities/Institutes 14 Cataract - Companies Involved in Therapeutics Development 15 EyeGate Pharmaceuticals, Inc. 15 Genisphere LLC 16 Omeros Corporation 17 Plex Pharmaceuticals, Inc. 18 Cataract - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 dexamethasone acetate - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 GL-249 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 lanosterol - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecule for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecule to Antagonize GPR161 for Central Nervous System Disorders, Oncology and Ophthalmology - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 VP-1001 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Cataract - Dormant Projects 39 Cataract - Discontinued Products 40 Cataract - Product Development Milestones 41 Featured News & Press Releases 41 Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables Number of Products under Development for Cataract, H2 2016 7 Number of Products under Development for Cataract - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Cataract - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016 15 Cataract - Pipeline by Genisphere LLC, H2 2016 16 Cataract - Pipeline by Omeros Corporation, H2 2016 17 Cataract - Pipeline by Plex Pharmaceuticals, Inc., H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Cataract - Dormant Projects, H2 2016 39 Cataract - Discontinued Products, H2 2016 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.